NIAID symposium in Buenos Aires: Formulating a comprehensive HIV/AIDS research agenda in developing countries

July 02, 2001

In conjunction with the International AIDS Society's 1st Conference on HIV Pathogenesis and Treatment in Buenos Aires, Argentina, the National Institute of Allergy and Infectious Diseases (NIAID) will conduct a special symposium entitled "Formulating a Comprehensive HIV/AIDS Research Agenda in Developing Countries" on July 7 at 1:00 p.m. in the Libertador Room of the Sheraton Buenos Aires Hotel (Tel: 54-11-43189000). Hosted by NIAID Director Anthony S. Fauci, M.D., the symposium will engage the presenters, panelists, and attendees in a dialogue on the significant challenges in international HIV/AIDS research.

Common themes from diverse geographic and cultural settings will be identified. The role that NIAID and NIH can play as partners with host countries in guiding and supporting the development of appropriate and effective research programs in these settings will be discussed.

The symposium will address two major questions in international HIV/AIDS research.

* How do we identify research needs and establish priorities in developing countries?

* What are the best ways to expand in-country research capacity to address these priorities?

The Symposium agenda and panel members are as follows:

13:00-13:20 Welcome and Opening Presentation
"NIH as a Partner in the HIV Research Agenda in Developing Nations"
Presenter: Anthony S. Fauci, M.D. (NIH/USA)
Note: Dr. Fauci's slide presentation will be posted at
on July 7 at 12:00 p.m. Eastern Time

13:20-13:30 Panel Introductions
Moderator: Carlos Del Rio, M.D. (Mexico)

13:30-13:45 "How do we identify research needs and establish priorities in developing countries?"
Presenter: Jose Esparza, M.D. (UNAIDS/Switzerland)
Note: Dr. Esparza's slide presentation will be posted at on July 7 at 12:00 P.M. Eastern Time

13:45-14:45 Panel/Audience Discussion

14:45-15:00 "What are the best ways to expand in-country research capacity to address these priorities?" Presenter: Prof. Patricio Garrahan, M.D. (Argentina)

15:00-16:00 Panel/Audience Discussion and Conclusions

Panel Members:

Hoosen Coovadia, M.D. (South Africa)
Jonathan Kaplan, M.D. (CDC/USA)
Paolo Miotti, M.D. (NIH/USA)
Praphan Phanuphak, M.D., Ph.D. (Thailand)
Jorge Sanchez, M.D., M.P.H. (Peru)
Mauro Schechter, M.D., Ph.D. (Brazil)
Graciela Touze (Argentina)
Mercedes Weissenbacher, M.D. (Argentina)


NIH and NIAID have a long and successful history of supporting international AIDS research, dating back to the early years of the AIDS epidemic. As discussed in the recent NIH Global AIDS Research Initiative and Strategic Plan (available at, NIH currently supports AIDS research activities at well over 300 sites in more than 100 countries. NIH funding for international AIDS research increased from $28 million in fiscal year 1990 to an estimated $154 million in fiscal years 2002.

NIAID international HIV/AIDS programs over the years have included the:

* Cornell/Haiti Project (1984-present)
* Projet SIDA Zaire (1984-1992)
* International Collaboration in AIDS Research (ICAR; 1988-1992)
* Preparation for AIDS Vaccine Evaluation (PAVE; 1993-1994)
* HIV Network for Prevention Trials (HIVNET; 1994-2000)
* HIV Prevention Trials Network (HPTN; 1999-present)
* HIV Vaccine Trials Network (HVTN; 1999-present)
* Comprehensive International Program of Research on AIDS (CIPRA, 2001-present)

NIAID recently developed a global HIV/AIDS research agenda with the goal of helping to provide the knowledge and resource base for the development of effective treatment and preventions strategies in developing countries. This agenda is delineated in the NIAID Global Health Research Plan for HIV/AIDS, Malaria and Tuberculosis, available at

Two recently launched programs are key to the NIAID international AIDS research effort: the HIV Prevention Trials Network (HPTN) and the HIV Vaccine Trials Network (HVTN), which have research sites in the United States, Latin America, Europe, Africa, Asia and the Caribbean. The HPTN focuses on several key areas of prevention research, including behavioral modification, interventions to prevent mother-to infant HIV transmission, and the development of topically applied microbicides for protection against HIV and other sexually transmitted pathogens. The HVTN will conduct all phases of clinical vaccine trials, from evaluating candidate vaccines for safety and the ability to stimulate immune responses, to testing vaccine efficacy.

In addition, the Comprehensive International Program of Research on AIDS (CIPRA) will provide long-term support for fundamental epidemiological, laboratory, and clinical studies on HIV/AIDS and concomitant infections, and enhance in-country capability to conduct relevant and ethically sound public health research in local populations.
NIAID is a component of the National Institutes of Health (NIH). NIAID supports basic and applied research to prevent, diagnose, and treat infectious and immune-mediated illnesses, including HIV/AIDS and other sexually transmitted diseases, tuberculosis, malaria, autoimmune disorders, asthma and allergies.

Press releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at

The National Institute of Allergy and Infectious Diseases is a component of the National Institutes of Health, U.S. Department of Health and Human Services

NIH/National Institute of Allergy and Infectious Diseases

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to